

2 **Erratum to: Pharmacokinetics in Patients with Chronic Liver**  
3 **Disease and Hepatic Safety of Incretin-Based Therapies**  
4 **for the Management of Type 2 Diabetes Mellitus**

5 **André J. Scheen**

6  
7 © Springer International Publishing Switzerland 2014

8 **Erratum to: Clin Pharmacokinet (2014) 53(9):773–785**  
9 **DOI 10.1007/s40262-014-0157-y**

10 Page 778, Table 3: The last two rows which previously  
11 read:

14	ALT >3 × ULN	46 (1.7)	64 (2.4)	0.10
15	AST >3 × ULN	43 (1.6)	48 (1.8)	0.67

19  
16 Should read

20	ALT >3 × ULN	64 (2.4)	46 (1.7)	0.10
21	AST >3 × ULN	48 (1.8)	43 (1.6)	0.67

A1 The online version of the original article can be found  
A2 under doi:10.1007/s40262-014-0157-y.

A3 A. J. Scheen (✉)  
A4 Division of Diabetes, Nutrition and Metabolic Disorders,  
A5 Department of Medicine, University of Liège, Liège, Belgium  
A6 e-mail: andre.scheen@chu.ulg.ac.be

A7 A. J. Scheen  
A8 Division of Clinical Pharmacology, Center for Interdisciplinary  
A9 Research on Medicines (CIRM), CHU Sart Tilman (B35),  
A10 University of Liège, 4000 Liège 1, Belgium